Immune response to sipuleucel-T in prostate cancer

Cancers

Volumn 4, Issue 2, 2012, Pages 420-441

  Thara, Eddie ^a   Dorff, Tanya B ^a   Averia Suboc, Monica ^a   Luther, Michael ^a   Reed, Mary E ^a   Pinski, Jacek K ^a   Quinn, David I ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Biomarkers; Castrate resistant prostate cancer; Immune response; Immunotherapy; Sipuleucel T

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CORTICOSTEROID; CYTOTOXIC AGENT; DOCETAXEL; GONADORELIN AGONIST; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PA 2024; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T; TICILIMUMAB; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELLULAR IMMUNITY; CHILL; CYTOKINE PRODUCTION; DONOR LYMPHOCYTE INFUSION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE SEQUENCE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FIBROSARCOMA; FLU LIKE SYNDROME; HOST RESISTANCE; HUMAN; HYPERHIDROSIS; HYPERTENSION; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION; INFUSION RELATED REACTION; INNATE IMMUNITY; MELANOMA; METASTASIS; MONOTHERAPY; MYELOABLATIVE CONDITIONING; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PATIENT SELECTION; PROSTATE CANCER; REVIEW; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; T LYMPHOCYTE ACTIVATION; TREATMENT PLANNING;

EID: 84862637106     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers4020420     Document Type: Review

References (108)

1. Jemal, A.; Siegel, R.; Xu, J.; Ward, E. Cancer statistics, 2011. CA Cancer J. Clin. 2010, 60, 277-300.
2. Eisenberger, M.A.; Blumenstein, B.A.; Crawford, E.D.; Miller, G.; McLeod, D.G.; Loehrer, P.J.; Wilding, G.; Sears, K.; Culkin, D.J.; Thompson, I.M., Jr.; et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 1998, 339, 1036-1042.
3. Melief, C.J. Cancer: Immune pact with the enemy. Nature 2007, 450, 803-804.
4. Grulich, A.E.; van Leeuwen, M.T.; Falster, M.O.; Vajdic, C.M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis. Lancet 2007, 370, 59-67.
5. Simard, E.P.; Shiels, M.S.; Bhatia, K.; Engels, E.A. Long-term cancer risk among people diagnosed with AIDS during childhood. Cancer Epidemiol. Biomarkers Prev. 2012, 21, 148-154.
6. Catalona, W.J.; Mann, R.; Nime, F.; Potvin, C.; Harty, J.I.; Gomolka, D.; Eggleston, J.C. Identification of complement-receptor lymphocytes (B cells) in lymph nodes and tumor infiltrates. J. Urol. 1975, 114, 915-921.
7. Kurihara, K.; Hashimoto, N. The pathological significance of langerhans cells in oral cancer. J. Oral. Pathol. 1985, 14, 289-298.
8. Gooden, M.J.; de Bock, G.H.; Leffers, N.; Daemen, T.; Nijman, H.W. The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis. Br. J. Cancer 2011, 105, 93-103.
9. Talmadge, J.E. Immune cell infiltration of primary and metastatic lesions: Mechanisms and clinical impact. Semin. Cancer Biol. 2011, 21, 131-138.
10. Vesalainen, S.; Lipponen, P.; Talja, M.; Syrjänen, K. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinoma. Eur. J. Cancer 1994, 30A, 1797-1803.
11. Yang, L.; Carbone, D.P. Tumor-host immune interactions and dendritic cell dysfunction. Adv. Cancer Res. 2004, 92, 13-27.
12. Zhang, H.; Melamed, J.; Wei, P.; Cox, K.; Frankel, W.; Bahnson, R.R.; Robinson, N.; Pyka, R.; Liu, Y.; Zheng, P. Concordant down-regulation of proto-oncogene PML and major histocompatibility antigen HLA class I expression in high-grade prostate cancer. Cancer Immun. 2003, 3, 2.
13. Ahmadzadeh, M.; Johnson, L.A.; Heemskerk, B.; Wunderlich, J.R.; Dudley, M.E.; White, D.E.; Rosenberg, S.A. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114, 1537-1544.
14. Chappell, D.B.; Restifo, N.P. T cell-tumor cell: A fatal interaction? Cancer Immunol. Immunother. 1998, 47, 65-71.
15. Curti, A.; Trabanelli, S.; Salvestrini, V.; Baccarani, M.; Lemoli, R.M. The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: Focus on hematology. Blood 2009, 113, 2394-2401.
16. Fukumura, D.; Kashiwagi, S.; Jain, R.K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 2006, 6, 521-534.
17. de Marzo, A.M.; Platz, E.A.; Sutcliffe, S.; Xu, J.; Gronberg, H.; Drake, C.G.; Nakai, Y.; Isaacs, W.B.; Nelson, W.G. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 2007, 7, 256-269.
18. Drake, C.G. Prostate cancer as a model for tumour immunotherapy. Nat. Rev. Immunol. 2010, 10, 580-593.
19. Drake, C.G.; Jaffee, E.; Pardoll, D.M. Mechanisms of immune evasion by tumors. Adv. Immunol. 2006, 90, 51-81.
20. Galsky, M.D.; Eisenberger, M.; Moore-Cooper, S.; Kelly, W.K.; Slovin, S.F.; DeLaCruz, A.; Lee, Y.; Webb, I.J.; Scher, H.I. Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate mln2704 in patients with progressive metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2008, 26, 2147-2154.
21. Kantoff, P.W.; Schuetz, T.J.; Blumenstein, B.A.; Glode, L.M.; Bilhartz, D.L.; Wyand, M.; Manson, K.; Panicali, D.L.; Laus, R.; Schlom, J.; et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based psa-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2010, 28, 1099-1105.
22. Pijpers, F.; Faint, R.; Saini, N. Therapeutic cancer vaccines. Nat. Rev. Drug Discov. 2005, 4, 623-624.
23. Eder, J.P.; Kantoff, P.W.; Roper, K.; Xu, G.X.; Bubley, G.J.; Boyden, J.; Gritz, L.; Mazzara, G.; Oh, W.K.; Arlen, P.; et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 2000, 6, 1632-1638.
24. Kaufman, H.L.; Wang, W.; Manola, J.; di Paola, R.S.; Ko, Y.J.; Sweeney, C.; Whiteside, T.L.; Schlom, J.; Wilding, G.; Weiner, L.M. Phase II randomized study of vaccine treatment of advanced prostate cancer (e7897): A trial of the eastern cooperative oncology group. J. Clin. Oncol. 2004, 22, 2122-2132.
25. Simons, J.W.; Sacks, N. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: The GVAX vaccine for prostate cancer. Urol. Oncol. 2006, 24, 419-424.
26. Higano, C.; Saad, F.; Somer, B.; Curti, B.; Petrylak, D.; Drake, C.G.; Schnell, F.; Redfern, C.H.; Schrijvers, D.; Sacks, N. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (crpc). In 2009 Genitourinary Cancers Symposium, Orlando, FL, USA, 26-28 February 2009; p. LBA150.
27. Small, E.J.; Demkow, T.; Gerritsen, W.R.; Rolland, F.; Hoskin, P.; Smith, D.C.; Parker, C.; Chondros, D.; Ma, J.; Hege, K. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (crpc). In 2009 Genitourinary Cancers Symposium, Orlando, FL, USA, 26-28 February 2009; p. A7.
28. Beer, T.M.; Slovin, S.F.; Higano, C.S.; Tejwani, S.; Dorff, T.B.; Stankevich, E.; Lowy, I.; Prostate Cancer Clinical Trials Consortium. Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). J. Clin. Oncol. 2008, 26, 5004.
29. Slovin, S.F.; Beer, T.M.; Higano, C.S.; Tejwani, S.; Hamid, O.; Picus, J.; Harzstark, A.; Scher, H.I.; Lan, Z.; Lowy, I.; et al. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 2009, 27, 5138.
30. Hodi, F.S.; O'Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711-723.
31. Mittendorf, E.A.; Sharma, P. Mechanisms of T-cell inhibition: Implications for cancer immunotherapy. Expert Rev. Vaccines 2010, 9, 89-105.
32. Brahmer, J.R.; Drake, C.G.; Wollner, I.; Powderly, J.D.; Picus, J.; Sharfman, W.H.; Stankevich, E.; Pons, A.; Salay, T.M.; McMiller, T.I.; et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28, 3167-3175.
33. Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B.; et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010, 363, 411-422.
34. Beer, T.M.; Bernstein, G.T.; Corman, J.M.; Glode, L.M.; Hall, S.J.; Poll, W.L.; Schellhammer, P.F.; Jones, L.A.; Xu, Y.; Kylstra, J.W.; et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin. Cancer Res. 2011, 17, 4558-4567.
35. Simons, J.W.; Jaffee, E.M.; Weber, C.E.; Levitsky, H.I.; Nelson, W.G.; Carducci, M.A.; Lazenby, A.J.; Cohen, L.K.; Finn, C.C.; Clift, S.M.; et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 1997, 57, 1537-1546.
36. Simons, J.W.; Mikhak, B.; Chang, J.F.; de Marzo, A.M.; Carducci, M.A.; Lim, M.; Weber, C.E.; Baccala, A.A.; Goemann, M.A.; Clift, S.M.; et al. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 1999, 59, 5160-5168.
37. Slovin, S.F. Prostate cancer vaccines: Maximizing a suboptimal immune response for improved outcome. Clin. Adv. Hematol. Oncol. 2007, 5, 972-980.
38. Higano, C.S.; Corman, J.M.; Smith, D.C.; Centeno, A.S.; Steidle, C.P.; Gittleman, M.; Simons, J.W.; Sacks, N.; Aimi, J.; Small, E.J. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008, 113, 975-984.
39. Cameron, F.; Whiteside, G.; Perry, C. Ipilimumab: First global approval. Drugs 2011, 71, 1093-1104.
40. A randomized study comparing 4 monthly doses of MDX-010 (CTLA-4) as a single agent or used in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer: [clinical trialsgov identifier nct00050596]. Available online: http://clinicaltrials.gov/ct2/show/NCT00050596/ (accessed on 22 November 2011).
41. Ebelt, K.F.; Babaryka, G.; Frankenberger, B.; Stief, C.G.; Eisenmenger, W.; Kirchner, T.; Schendel, D.J.; Noessner, E. Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters. Eur. J. Cancer 2009, 45, 1664-1672.
42. Qian, B.-Z.; Pollard, J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141, 39-51.
43. Kaplan, R.N.; Psaila, B.; Lyden, D. Niche-to-niche migration of bone-marrow-derived cells. Trends Mol. Med. 2007, 13, 72-81.
44. Valastyan, S.; Weinberg, R.A. Tumor metastasis: Molecular insights and evolving paradigms. Cell 2011, 147, 275-292.
45. Jenq, R.R.; van den Brink, M.R. Allogeneic haematopoietic stem cell transplantation: Individualized stem cell and immune therapy of cancer. Nat. Rev. Cancer 2010, 10, 213-221.
46. Childs, R.; Chernoff, A.; Contentin, N.; Bahceci, E.; Schrump, D.; Leitman, S.; Read, E.J.; Tisdale, J.; Dunbar, C.; Linehan, W.M.; et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 2000, 343, 750-758.
47. Tykodi, S.S.; Warren, E.H.; Thompson, J.A.; Riddell, S.R.; Childs, R.W.; Otterud, B.E.; Leppert, M.F.; Storb, R.; Sandmaier, B.M. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: Toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin. Cancer Res. 2004, 10, 7799-7811.
48. Rini, B.I.; Zimmerman, T.; Stadler, W.M.; Gajewski, T.F.; Vogelzang, N.J. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: Feasibility, engraftment, and clinical results. J. Clin. Oncol. 2002, 20, 2017-2024.
49. Rini, B.I.; Halabi, S.; Barrier, R.; Margolin, K.A.; Avigan, D.; Logan, T.; Stadler, W.M.; McCarthy, P.L.; Linker, C.A.; Small, E.J. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: A CALGB intergroup phase II study. Biol. Blood Marrow Transplant. 2006, 12, 778-785.
50. Nishiyama, T.; Kishi, K.; Deguchi, T.; Mukaiyama, T.; Terunuma, M. High-dose chemotherapy with peripheral blood stem-cell transplantation for hormone-refractory advanced carcinoma of the prostate: Experience of two cases. Int. J. Urol. 1996, 3, 320-323.
51. O'Sullivan, J.M.; Norman, A.R.; McCready, V.R.; Flux, G.; Buffa, F.M.; Johnson, B.; Coffey, J.; Cook, G.; Treleaven, J.; Horwich, A.; et al. A phase 2 study of high-activity 186Re-HEDP with autologous peripheral blood stem cell transplant in progressive hormone-refractory prostate cancer metastatic to bone. Eur. J. Nucl. Med. Mol. Imaging 2006, 33, 1055-1061.
52. Smith-Jones, P.M.; Vallabhajosula, S.; Navarro, V.; Bastidas, D.; Goldsmith, S.J.; Bander, N.H. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing lncap human prostate tumor. J. Nucl. Med. 2003, 44, 610-617.
53. 177Lu-J591) in patients (pts) with metastatic androgen independent prostate cancer (AIPC). J. Clin. Oncol. 2006, 24, 4613.
54. Milowsky, M.I.; Nanus, D.M.; Kostakoglu, L.; Sheehan, C.E.; Vallabhajosula, S.; Goldsmith, S.J.; Ross, J.S.; Bander, N.H. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J. Clin. Oncol. 2007, 25, 540-547.
55. Milowsky, M.I.; Galsky, M.; George, D.J.; Lewin, J.M.; Rozario, C.P.; Marshall, T.; Chang, M.; Nanus, D.M.; Webb, I.J.; Scher, H.I. Phase I/II trial of the prostate-specific membrane antigen (psma)-targeted immunoconjugate mln2704 in patients (pts) with progressive metastatic castration resistant prostate cancer. J. Clin. Oncol. 2006, 24, 4500.
56. Sallusto, F.; Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 1994, 179, 1109-1118.
57. Klein, C.; Bueler, H.; Mulligan, R.C. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J. Exp. Med. 2000, 191, 1699-1708.
58. ®) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A phase 2 trial. Prostate 2004, 60, 197-204.
59. Small, E.J.; Fratesi, P.; Reese, D.M.; Strang, G.; Laus, R.; Peshwa, M.V.; Valone, F.H. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 2000, 18, 3894-3903.
60. ®) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin. Prostate Cancer 2005, 4, 55-60.
61. Burch, P.A.; Breen, J.K.; Buckner, J.C.; Gastineau, D.A.; Kaur, J.A.; Laus, R.L.; Padley, D.J.; Peshwa, M.V.; Pitot, H.C.; Richardson, R.L.; et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer Res. 2000, 6, 2175-2182.
62. Small, E.J.; Schellhammer, P.F.; Higano, C.S.; Redfern, C.H.; Nemunaitis, J.J.; Valone, F.H.; Verjee, S.S.; Jones, L.A.; Hershberg, R.M. Placebo-controlled phase iii trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 2006, 24, 3089-3094.
63. Higano, C.S.; Schellhammer, P.F.; Small, E.J.; Burch, P.A.; Nemunaitis, J.; Yuh, L.; Provost, N.; Frohlich, M.W. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115, 3670-3679.
64. Hall, S.J.; Klotz, L.; Pantuck, A.J.; George, D.J.; Whitmore, J.B.; Frohlich, M.W.; Sims, R.B. Integrated safety data from 4 randomized, double-blind, controlled trials of autologous cellular immunotherapy with sipuleucel-T in patients with prostate cancer. J. Urol. 2011, 186, 877-881.
65. Hoos, A.; Parmiani, G.; Hege, K.; Sznol, M.; Loibner, H.; Eggermont, A.; Urba, W.; Blumenstein, B.; Sacks, N.; Keilholz, U.; et al. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 2007, 30, 1-15.
66. Wolchok, J.D.; Hoos, A.; O'Day, S.; Weber, J.S.; Hamid, O.; Lebbe, C.; Maio, M.; Binder, M.; Bohnsack, O.; Nichol, G.; et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin. Cancer Res. 2009, 15, 7412-7420.
67. Hoos, A.; Eggermont, A.M.; Janetzki, S.; Hodi, F.S.; Ibrahim, R.; Anderson, A.; Humphrey, R.; Blumenstein, B.; Old, L.; Wolchok, J. Improved endpoints for cancer immunotherapy trials. J. Natl. Cancer Inst. 2010, 102, 1388-1397.
68. Madan, R.A.; Gulley, J.L.; Fojo, T.; Dahut, W.L. Therapeutic cancer vaccines in prostate cancer: The paradox of improved survival without changes in time to progression. Oncologist 2010, 15, 969-975.
69. Scher, H.I.; Halabi, S.; Tannock, I.; Morris, M.; Sternberg, C.N.; Carducci, M.A.; Eisenberger, M.A.; Higano, C.; Bubley, G.J.; Dreicer, R.; et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group. J. Clin. Oncol. 2008, 26, 1148-1159.
70. Ryan, C.J.; Shah, S.; Efstathiou, E.; Smith, M.R.; Taplin, M.E.; Bubley, G.J.; Logothetis, C.J.; Kheoh, T.; Kilian, C.; Haqq, C.M.; et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin. Cancer Res. 2011, 17, 4854-4861.
71. Laus, R.; Yang, D.; Ruegg, C.; Shapero, M.; Slagle, P.; Small, E.; Burch, P.; Valone, F.H. Dendritic cell immunotherapy of prostate cancer: Preclinical models and early clinical experience. Cancer Res. Ther. Control 2001, 11, 1-10.
72. Stewart, F.P.; dela Rosa, C.P.; Sheikh, N.A.; McNeel, D.G.; Frohlich, M.W.; Urdal, D.L.; Provost, N.M. Correlation between product parameters and overall survival in three trials of sipuleucel-T, an autologous active cellular immunotherapy for the treatment of prostate cancer. J. Clin. Oncol. 2010, 28, 4552.
73. Sims, R.B. Development of sipuleucel-T: Autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Vaccine 2011, in press.
74. Sheikh, N.A.; Jones, L.A. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol. Immunother. 2008, 57, 1381-1390.
75. Sheikh, N.; dela Rosa, C.; Frohlich, M.; Urdal, D.; Provost, N. Sipuleucel-T treatment results in sequential ex vivo activation of apcs and T cells during the culture step-Evidence for in vivo immunological priming. Presented at the AACR 101st Annual Meeting 2010, Washington, DC, USA, 21 April 2010.
76. Wesley, J.D.; Chadwick, E.; Kuan, L.-Y.; dela Rosa, C.; Frohlich, M.; Urdal, D. Characterization of antigen specific T cell activation and cytokine expression induced by sipuleucel-T. J. Immunother. 2010, 33, 912-913.
77. Sheikh, N.A.; Wesley, J.D.; Chadwick, E.; Perdue, N.; dela Rosa, C.; Frohlich, M.W.; Stewart, F.P.; Urdal, D.L.; Dendreon Corporation, Seattle, WA, USA. Characterization of antigen specifric T-cell activation and cytokine expression induced by sipuleucel-T. J. Clin. Oncol. 2011, 29, 155.
78. Butterfield, L.H.; Disis, M.L.; Khleif, S.N.; Balwit, J.M.; Marincola, F.M. Immuno-oncology biomarkers 2010 and beyond: Perspectives from the isbtc/sitc biomarker task force. J. Transl. Med. 2010, 8, 130.
79. Mercader, M.; Bodner, B.K.; Moser, M.T.; Kwon, P.S.; Park, E.S.; Manecke, R.G.; Ellis, T.M.; Wojcik, E.M.; Yang, D.; Flanigan, R.C.; et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc. Natl. Acad. Sci. USA 2001, 98, 14565-14570.
80. Oliver, R.T.; Gallagher, C.J. Intermittent endocrine therapy and its potential for chemoprevention of prostate cancer. Cancer Surv. 1995, 23, 191-207.
81. Drake, C.G.; Doody, A.D.; Mihalyo, M.A.; Huang, C.T.; Kelleher, E.; Ravi, S.; Hipkiss, E.L.; Flies, D.B.; Kennedy, E.P.; Long, M.; et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell 2005, 7, 239-249.
82. Roden, A.C.; Moser, M.T.; Tri, S.D.; Mercader, M.; Kuntz, S.M.; Dong, H.; Hurwitz, A.A.; McKean, D.J.; Celis, E.; Leibovich, B.C.; et al. Augmentation of T cell levels and responses induced by androgen deprivation. J. Immunol. 2004, 173, 6098-6108.
83. Morse, M.D.; McNeel, D.G. Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses. Hum. Immunol. 2010, 71, 496-504.
84. Friedman, E.J. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr. Pharm. Des. 2002, 8, 1765-1780.
85. McBride, W.H.; Chiang, C.S.; Olson, J.L.; Wang, C.C.; Hong, J.H.; Pajonk, F.; Dougherty, G.J.; Iwamoto, K.S.; Pervan, M.; Liao, Y.P. A sense of danger from radiation. Radiat. Res. 2004, 162, 1-19.
86. Demaria, S.; Bhardwaj, N.; McBride, W.H.; Formenti, S.C. Combining radiotherapy and immunotherapy: A revived partnership. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63, 655-666.
87. Nesslinger, N.J.; Sahota, R.A.; Stone, B.; Johnson, K.; Chima, N.; King, C.; Rasmussen, D.; Bishop, D.; Rennie, P.S.; Gleave, M.; et al. Standard treatments induce antigen-specific immune responses in prostate cancer. Clin. Cancer Res. 2007, 13, 1493-1502.
88. Zhang, G.; Zhang, L.; Duff, G.W. A negative regulatory region containing a glucocorticosteroid response element (nGRE) in the human interleukin-1beta gene. DNA Cell Biol. 1997, 16, 145-152.
89. Meagher, L.C.; Cousin, J.M.; Seckl, J.R.; Haslett, C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J. Immunol. 1996, 156, 4422-4428.
90. Chatham, W. Glucocorticoid effects on the immune system. Available online: http://www.uptodate.com/contents/glucocorticoid-effects-on-the-immune-system/ (accessed on 2 April 2012).
91. de Bono, J.S.; Oudard, S.; Ozguroglu, M.; Hansen, S.; Machiels, J.P.; Kocak, I.; Gravis, G.; Bodrogi, I.; Mackenzie, M.J.; Shen, L.; et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 2010, 376, 1147-1154.
92. Hammerstrom, A.E.; Cauley, D.H.; Atkinson, B.J.; Sharma, P. Cancer immunotherapy: Sipuleucel-T and beyond. Pharmacotherapy 2011, 31, 813-828.
93. Gulley, J.; Madan, R.; Arlen, P. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 2007, 25, B89-B96.
94. Emens, L.A.; Machiels, J.P.; Reilly, R.T.; Jaffee, E.M. Chemotherapy: Friend or foe to cancer vaccines? Curr. Opin. Mol. Ther. 2001, 3, 77-84.
95. Garnett, C.T.; Schlom, J.; Hodge, J.W. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: Effects of docetaxel on immune enhancement. Clin. Cancer Res. 2008, 14, 3536-3544.
96. Garrido, C.; Romero, I.; Berruguilla, E.; Cancela, B.; Algarra, I.; Collado, A.; Garcia-Lora, A.; Garrido, F. Immunotherapy eradicates metastases with reversible defects in mhc class I expression. Cancer Immunol. Immunother. 2011, 60, 1257-1268.
97. Aptsiauri, N.; Cabrera, T.; Mendez, R.; Garcia-Lora, A.; Ruiz-Cabello, F.; Garrido, F. Role of altered expression of HLA class I molecules in cancer progression. Adv. Exp. Med. Biol. 2007, 601, 123-131.
98. Aptsiauri, N.; Carretero, R.; Garcia-Lora, A.; Real, L.M.; Cabrera, T.; Garrido, F. Regressing and progressing metastatic lesions: Resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol. Immunother. 2008, 57, 1727-1733.
99. Garrido, F.; Cabrera, T.; Aptsiauri, N. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy. Int. J. Cancer 2010, 127, 249-256.
100. Arlen, P.M.; Gulley, J.L.; Parker, C.; Skarupa, L.; Pazdur, M.; Panicali, D.; Beetham, P.; Tsang, K.Y.; Grosenbach, D.W.; Feldman, J.; et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res. 2006, 12, 1260-1269.
101. Gribben, J.G.; Ryan, D.P.; Boyajian, R.; Urban, R.G.; Hedley, M.L.; Beach, K.; Nealon, P.; Matulonis, U.; Campos, S.; Gilligan, T.D.; et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin. Cancer Res. 2005, 11, 4430-4436.
102. Antonia, S.J.; Mirza, N.; Fricke, I.; Chiappori, A.; Thompson, P.; Williams, N.; Bepler, G.; Simon, G.; Janssen, W.; Lee, J.H.; et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 2006, 12, 878-887.
103. Petrylak, D. Defining the optimal role of immunotherapy and chemotherapy: Advanced prostate cancer patients who receive sipuleucel-T followed by docetaxel derive the greatest survival benefit. In Chemotherapy Symposium 14th Annual Meeting, New York, NY, USA, 8-11 November, 2006.
104. Sheikh, N.A.; Small, E.J.; Quinn, D.I.; Higano, C.S.; Lin, D.W.; Wesley, J.D.; Haynes, H.; Stewart, F.P.; Poehlein, C.H.; Trager, J.B. Sipuleucel-T product characterization across different disease states of prostate cancer. J. Clin. Oncol. 2012, 30, 42.
105. Waeckerle-Men, Y.; Uetz-von Allmen, E.; Fopp, M.; von Moos, R.; Bohme, C.; Schmid, H.P.; Ackermann, D.; Cerny, T.; Ludewig, B.; Groettrup, M.; et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol. Immunother. 2006, 55, 1524-1533.
106. Kim, D.W.; Krishnamurthy, V.; Bines, S.D.; Kaufman, H.L. TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: Lessons learned and future development. Hum. Vaccin. 2010, 6, 784-791.
107. Wolchok, J.D.; Weber, J.S.; Hamid, O.; Lebbe, C.; Maio, M.; Schadendorf, D.; de Pril, V.; Heller, K.; Chen, T.T.; Ibrahim, R.; et al. Ipilimumab efficacy and safety in patients with advanced melanoma: A retrospective analysis of HLA subtype from four trials. Cancer Immun. 2010, 10, 9.
108. Small, E.J.; Higano, C.S.; Kantoff, P.W.; Whitmore, J.B.; Frohlich, M.W.; Petrylak, D.P. Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mcrpc): Results from three randomized phase III trials. J. Clin. Oncol. 2011, 29, 4661.